Insmed Sees Unusually Large Options Volume (NASDAQ:INSM)

Key Points

• Unusually high options activity: Investors purchased 7,706 Insmed call options, 121% above typical volume, signaling increased bullish speculation. The stock rose 15.1% to $111.59 on trading volume well above average.
• Strong revenue and guidance growth: Third-quarter revenue reached $524.4 million, up 268.4% year over year and above estimates, while Insmed raised its 2026 revenue outlook for BRINSUPRI and ARIKAYCE. However, the company’s $0.46 per-share loss was wider than analysts expected.
• Analysts remain broadly positive: Insmed has a consensus “Moderate Buy” rating and an average price target of $197.26, despite one recent analyst target reduction. Insiders have recently sold substantial amounts of stock.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) saw some unusual options trading on Thursday. Stock investors acquired 7,706 call options on the stock. This represents an increase of 121% compared to the typical volume of 3,483 call options.

Insmed Stock Up 15.1%

INSM stock traded up $14.61 during mid-day trading on Thursday, hitting $111.59. 11,217,795 shares of the company were exchanged, compared to its average volume of 2,982,364. The firm has a fifty day simple moving average of $113.29 and a 200 day simple moving average of $126.28. The company has a market capitalization of $24.37 billion, a PE ratio of -27.15 and a beta of 0.83. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.07). The firm had revenue of $524.43 million for the quarter, compared to the consensus estimate of $499.06 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The company's quarterly revenue was up 268.4% on a year-over-year basis. During the same period in the prior year, the business earned ($1.75) EPS. On average, research analysts forecast that Insmed will post -1.60 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. UBS Group reissued a "buy" rating on shares of Insmed in a research report on Thursday, October 8th. BMO Capital Markets reiterated an "outperform" rating on shares of Insmed in a report on Tuesday, October 6th. Mizuho set a $154.00 target price on Insmed in a research report on Thursday. Truist Financial reissued a "buy" rating and set a $195.00 price target (up from $185.00) on shares of Insmed in a research report on Monday, August 10th. Finally, Morgan Stanley dropped their price objective on shares of Insmed from $218.00 to $213.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $197.26.

Insider Buying and Selling at Insmed

In related news, Director David R. Brennan sold 25,000 shares of the company's stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the transaction, the director owned 39,238 shares of the company's stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Roger Adsett sold 239,850 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company's stock, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.10% of the company's stock.

Institutional Investors Weigh In On Insmed

Large investors have recently added to or reduced their stakes in the stock. Sei Investments Co. grew its stake in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock worth $228,239,000 after purchasing an additional 505,624 shares during the last quarter. NWI Management LP boosted its stake in shares of Insmed by 2.6% during the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company's stock worth $165,809,000 after acquiring an additional 25,540 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Insmed by 18.8% in the 1st quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company's stock worth $149,860,000 after acquiring an additional 145,106 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Insmed by 480.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company's stock valued at $144,591,000 after purchasing an additional 1,048,518 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Insmed in the 2nd quarter valued at $139,966,000.

More Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raised outlook and strong BRINSUPRI growth: Insmed increased its 2026 revenue guidance for BRINSUPRI to $1.35 billion-$1.40 billion and for ARIKAYCE to $460 million-$470 million. BRINSUPRI generated $400.1 million in third-quarter revenue, up 29% from the second quarter. Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Revenue exceeded expectations: Total third-quarter revenue reached $524.4 million, up 268.4% year over year and above the roughly $499.1 million analyst consensus. ARIKAYCE revenue rose 9% year over year to $124.4 million. Insmed Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Loss narrowed substantially: Insmed reported a third-quarter loss of $0.46 per share, compared with a $1.75 loss in the year-earlier period. The company also launched BRINSUPRI tablets in Japan, adding a potential international growth opportunity. Insmed Raises FY26 Revenue Outlook for BRINSUPRI and ARIKAYCE
• Neutral Sentiment: Unusually high call-option activity: Traders purchased 7,706 call options, 121% above average volume. This indicates increased bullish speculation, but options activity alone does not establish a fundamental change in valuation.
• Negative Sentiment: Quarterly EPS missed estimates: The $0.46 per-share loss was wider than the consensus estimate of a $0.39 loss, creating a counterpoint to the revenue and guidance strength. Insmed Quarterly Earnings Report
• Negative Sentiment: Analyst price-target reduction: Raymond James lowered its Insmed price target from $187 to $173, signaling more cautious valuation expectations. Raymond James Cuts Target for Insmed Stock

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed's lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.